Literature DB >> 15280387

Carbon monoxide promotes Fas/CD95-induced apoptosis in Jurkat cells.

Ruiping Song1, Zhihong Zhou, Peter K M Kim, Richard A Shapiro, Fang Liu, Christiane Ferran, Augustine M K Choi, Leo E Otterbein.   

Abstract

A properly functioning immune system is dependent on programmed cell death/apoptosis at virtually every stage of lymphocyte development and activity. Carbon monoxide (CO), an enzymatic product of heme oxyenase-1, has been shown to possess anti-apoptotic effects in a number of different model systems. The purpose of the present study was to expand on this knowledge to determine the role of CO in the well established model of Fas/CD95-induced apoptosis in Jurkat cells, and to determine the mechanism by which CO can modulate T-cell apoptosis. Exposure of Jurkat cells to CO resulted in augmentation in Fas/CD95-induced apoptosis, which correlated with CO-induced up-regulation of the pro-apoptotic protein FADD as well as activation of caspase-8, -9, and -3 while simultaneously down-regulating the anti-apoptotic protein BCL-2. These effects of CO were lost with overexpression of the small interfering RNA of FADD. CO, as demonstrated previously in endothelial cells, was also anti-apoptotic in Jurkat cells against tumor necrosis factor and etoposide. We further demonstrate that this pro-apoptotic effect of CO was independent of reactive oxygen species production and involved inhibition in Fas/CD95-induced activation of the pro-survival ERK MAPK. We conclude that in contrast to other studies showing the anti-apoptotic effects of CO, Fas/CD95-induced cell death in Jurkat cells is augmented by exposure to CO and that this occurs in part via inhibition in the activation of ERK MAPK. These data begin to elucidate specific differences with regard to the effects of CO and cell death pathways and provide important and valuable insight into potential mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280387     DOI: 10.1074/jbc.M406105200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis.

Authors:  Zhaoyu Jin; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

Review 2.  Carbon monoxide as an endogenous vascular modulator.

Authors:  Charles W Leffler; Helena Parfenova; Jonathan H Jaggar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-15       Impact factor: 4.733

3.  Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions.

Authors:  Michael Madigan; Fateh Entabi; Brian Zuckerbraun; Patricia Loughran; Edith Tzeng
Journal:  J Vasc Surg       Date:  2014-01-11       Impact factor: 4.268

Review 4.  The therapeutic potential of carbon monoxide.

Authors:  Roberto Motterlini; Leo E Otterbein
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

Review 5.  The social network of carbon monoxide in medicine.

Authors:  Barbara Wegiel; Douglas W Hanto; Leo E Otterbein
Journal:  Trends Mol Med       Date:  2012-11-08       Impact factor: 11.951

6.  Heme oxygenase-1 inhibits basophil maturation and activation but promotes its apoptosis in T helper type 2-mediated allergic airway inflammation.

Authors:  Wenwei Zhong; Caixia Di; Jiajia Lv; Yanjie Zhang; Xiaoliang Lin; Yufan Yuan; Jie Lv; Zhenwei Xia
Journal:  Immunology       Date:  2016-02-08       Impact factor: 7.397

7.  Synthesis and assessment of CO-release capacity of manganese carbonyl complexes derived from rigid α-diimine ligands of varied complexity.

Authors:  Jorge Jimenez; Indranil Chakraborty; Pradip K Mascharak
Journal:  Eur J Inorg Chem       Date:  2015-09-30       Impact factor: 2.524

8.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

Review 9.  Carbon monoxide in the treatment of sepsis.

Authors:  Kiichi Nakahira; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-23       Impact factor: 5.464

Review 10.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.